Minoryx gains FDA approval to initiate a Phase 3 clinical trial in patients with cerebral adrenoleukodystrophy
Mataró, Barcelona, Spain, May 31, 2023 - Minoryx Therapeutics, a registration stage biotech company focused on the development of therapies for orphan central nervous system (CNS) disorders, today announces the US Food and Drug Administration (FDA) approval of its Phase 3 clinical trial (CALYX) of lead candidate leriglitazone, to treat adult male X-linked Adrenoleukodystrophy (X-ALD) patients with cerebral adrenoleukodystrophy (cALD).
31/05/2023
Claudia Zylberberg appointed as independent board member of POCare business subsidiary of Orgenesis
Germantown, Maryland, US, May 30, 2023 - Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene therapies (CGTs), today announced that cell and gene therapy pioneer Claudia Zylberberg, PhD has been appointed as an independent board member and senior advisor of its Morgenesis LLC (“Morgenesis”) point-of-care . . .
30/05/2023
eXmoor pharma completes USD 35 million Series A to expand cell and gene therapy manufacturing capabilities
Bristol, UK, May 30, 2023 – eXmoor pharma, the end-to-end cell and gene therapy (CGT) manufacturing partner, today announced the close of a USD 35 million Series A financing round, from new investor Kineticos Ventures and existing investor MVM Partners. The funding will help launch eXmoor’s Cell and Gene Therapy Centre, a 65,000 sq ft GMP manufacturing facility, purpose-built to . . .
30/05/2023
Immutep selects Charles River laboratories for IMP761’s GLP toxicology study
Sydney, Australia, May 30, 2023 – Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces it has entered into an agreement with Charles River under which Charles River will conduct a GLP toxicology study for IMP761, Immutep's proprietary . . .
30/05/2023
BioSenic provides update regarding current license agreement with Phebra
Mont-Saint-Guibert, Belgium, May 29 2023, 7.00am CET – BioSenic (Euronext Brussels and Paris: BIOS), the clinical stage company specializing in serious autoimmune and inflammatory diseases and cell repair, today announces the amendment of the license agreement between its affiliate Medsenic SAS and Phebra Pty Ltd, the leading Australian developer, manufacturer and supplier of high quality and innovative pharmaceuticals.
29/05/2023
Immutep announces publication of abstracts for ASCO 2023 Annual Meeting
SYDNEY, AUSTRALIA, May 26, 2023 - Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces data from Part C of its TACTI-002 Phase II trial has been published in an abstract available on the 2023 American Society of Clinical Oncology’s (ASCO) . . .
26/05/2023
TrakCel announces launch of OCELLOS Core orchestration product for early-stage personalized cell therapy development
Cardiff, UK, May 25, 2023 - TrakCel, the leading and proven provider of cellular orchestration systems to the global cell and gene therapy (CGT) industry, today announces the launch of OCELLOS Core, its latest product in the OCELLOS range of leading advanced therapy orchestration products. TrakCel will make OCELLOS Core available to customers from end of July 2023.
25/05/2023
CellProthera enters final recruitment stage for phase I/IIb post-myocardial infarction therapy study
Mulhouse, France, May 25, 2023 – CellProthera, a regenerative cell therapy developer specializing in cardiology and myocardial infarction, today announces the final stage of its phase I/IIb clinical trial for its ProtheraCytes(R) cell therapy to prevent heart failure in patients following severe acute myocardial infarction . . .
25/05/2023
Terumo Blood and Cell Technologies optimizing cell therapy production through industry’s first apheresis training for cell therapy manufacturers
Lakewood, Colorado, US, May 25, 2023 – Terumo Blood and Cell Technologies (Terumo BCT), a medical technology company, launched the first training program of its kind to help cell and gene therapy manufacturers improve their cell collection processes and accelerate the commercialization of therapeutics. The new program trains participants in apheresis. This procedure is used to collect cells — an important step in making cell therapies for patients in need.
25/05/2023
Immutep doses first patient in AIPAC-003 phase II/III trial for metastatic
breast cancer
Sydney, Australia, May 25, 2023 – Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces the first patient has been enrolled and safely dosed at a European clinical site for its integrated Phase II/III AIPAC-003 trial in metastatic breast cancer.
25/05/2023
Immutep announces promising new clinical data from triple combination therapy in INSIGHT-003 trial
Sydney, Australia, May 24, 2023 – Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces new encouraging clinical data in first-line non-small cell lung cancer from INSIGHT-003 . . .
24/05/2023
BioSenic and Pluristyx sign term sheet for market availability of ALLOB mesenchymal cells
Mont-Saint-Guibert, Belgium, May 24, 2023 – BioSenic (Euronext Brussels and Paris: BIOS), the clinical stage company specializing in serious autoimmune and inflammatory diseases and cell repair, today announces the signing of a term sheet with Pluristyx, a leading provider of gene-edited iPSC . . .
24/05/2023
Orgenesis Academy graduates first class of cell and gene therapy experts from theraCell Laboratories-backed master’s program
Germantown, Maryland, US, May 22, 2023 - Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene therapies (CGTs), today announced the first graduating class from a unique Master of Science degree program in Cell and Gene Therapies . . .
22/05/2023
BioSenic provides first quarter 2023 business update
Mont-Saint-Guibert, Belgium, May 22, 2023 – BioSenic (Euronext Brussels and Paris: BIOS), the clinical stage company specializing in serious autoimmune and inflammatory diseases and cell repair, today announces its business update for the first quarter, ended 31 March 2023.
22/05/2023
Orgenesis to participate in Benchmark’s third Annual Healthcare House Call Virtual 1x1 Investor Conference on May 23, 2023
Germantown, Maryland, US, May 19, 2023 – Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene therapies (CGT) at the point of care, today announced that Vered Caplan, CEO of Orgenesis, will be participating in the Benchmark . . .
19/05/2023
Orgenesis announces collaboration agreement with SCTbio to expand POCare sites in the Czech Republic and enhance capabilities for the production of lentivirus vectors
Germantown, Maryland, US and Prague, Czech Republic – May 18, 2023 – Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis”), a global biotech company working to unlock the full potential of cell and gene therapies (CGT) through its US-based point-of-care (POCare) services subsidiary, Morgenesis LLC (“Morgenesis”), has signed a collaboration agreement with SCTbio . . .
18/05/2023
BioSenic reacquires global IP rights and provides an update on JTA-004 development
Mont-Saint-Guibert, Belgium, May 17th, 2023 – BioSenic (Euronext Brussels and Paris: BIOS), the clinical stage company specializing in serious autoimmune and inflammatory diseases and cell repair, today announces an update to its future plans for clinical development of BioSenic’s enhanced viscosupplement JTA. This includes BioSenic reacquiring intellectual property rights for the therapy.
17/05/2023
Immutep receives positive feedback from FDA on late-stage clinical development of eftilagimod alpha in non-small cell lung cancer
Sydney, Australia, May 16, 2023 – Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces it has received positive feedback from the US Food and Drug Administration . . .
16/05/2023
BioSenic to host Annual General Meeting on June 14 2023
Mont-Saint-Guibert, Belgium, May 15, 2023 – BioSenic (Euronext Brussels and Paris: BIOS), the clinical stage company specializing in serious autoimmune and inflammatory diseases and cell repair, invites its shareholders and the holders of registered subscription rights and registered convertible bonds of the Company to the Annual General Meeting to be held on Wednesday 14 June 2023 as from 4:00 pm CEST, at Osborne Clarke offices, Bastion Tower, Place du Champ de Mars 5, 1050 Brussels, Belgium.
15/05/2023
Cellular Origins partners with ScaleReady to simplify, standardise, and automate cell therapy manufacturing
Cambridge, UK, and St. Paul, MN, USA, 11 May 2023: Cellular Origins, a TTP Company focused on enabling scalable, cost-effective and efficient manufacture of cell and gene therapies (CGTs), has today announced a collaborative partnership with ScaleReady, a joint venture between Bio-Techne, Fresenius Kabi and Wilson Wolf that brings together process development expertise, tools and technologies for scalable CGT manufacturing. The partnership aims to automate portions of ScaleReady’s CGT manufacturing workflow by using Cellular Origin’s robotic system for sterile liquid transfer.
11/05/2023
Orgenesis secures an additional USD 5 million investment from Metalmark Capital to accelerate growth of Point-of-Care service subsidiary
Germantown, Md. US, May 10, 2023 - Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene therapies (CGT) at the point of care, and Metalmark Capital Partners (“Metalmark”), a leading private equity firm with extensive expertise in the healthcare sector, today announced that Metalmark has agreed to make an additional growth investment of USD 5 million
10/05/2023
Orgenesis provides business update for the first quarter of 2023 and reports continued progress on its POCare strategy
Germantown, Md. US, May 10, 2023 - Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene therapies (CGT), today provided a business update for the first quarter ended March 31, 2023.
10/05/2023
BioSenic identifies key biomarkers for cGvHD and submits patent to EPO
Mont-Saint-Guibert, Belgium, May 4, 2023 – BioSenic (Euronext Brussels and Paris: BIOS), the clinical stage company specializing in serious autoimmune and inflammatory diseases and cell repair, today announces the submission of a key patent in the use of its ATO platform.
04/05/2023
Immutep Announces KOL Event Focused on Eftilagimod Alpha in Non-Small Cell Lung Cancer and Head & Neck Squamous Cell Carcinoma
Sydney, Australia, May 2, 2023 - Immutep Limited (ASX: IMM; NASDAQ: IMMP), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces a Key Opinion Leader (KOL) event will be hosted by Ladenburg Thalmann & Co, Inc., on Tuesday, May 9, 2023, from 11.30am – 1.00pm ET.
02/05/2023
Immutep Receives Approval to Initiate INSIGHT-005 Trial Evaluating Eftilagimod Alpha and Anti-PD-L1 Therapy BAVENCIO(R)
Sydney, Australia, 1 May 2023 – Immutep Limited (ASX: IMM; NASDAQ: IMMP), a clinical-stage biotechnology company developing novel LAG-3 immunotherapiesfor cancer and autoimmune disease, today announces it has received regulatory approval from the Paul-Ehrlich-Institut (“PEI”) . . .
01/05/2023
BioSenic announces 2022 full-year result
Mont-Saint-Guibert, Belgium, April 27, 2023 – BIOSENIC (Euronext Brussels and Paris: BIOS), the company specializing in serious autoimmune and inflammatory diseases and cell repair, today announces its business update and full year financial results for the year ending 31 December 2022, prepared in accordance with IFRS as adopted by the European Union.
27/04/2023
Immutep quarterly activities report and Appendix 4C Q3 FY23
Sydney, Australia, April 27, 2023 – Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel LAG-3 related immunotherapy treatments for cancer and autoimmune diseases, provides an update on the ongoing development of its product candidates, eftilagimod alpha (efti) and IMP761 for the quarter ended 31st March 2023 (Q3 FY23).
27/04/2023
Immutep appoints Dr. Florian Vogl as Chief Medical Officer
Sydney, Australia, April 26, 2023 – Immutep Limited (ASX: IMM; NASDAQ: IMMP), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune diseases, today announces that Florian D. Vogl, M.D., Ph.D., MSc, has been appointed as Chief Medical Officer (CMO) with effect from May 1, 2023.
26/04/2023
Orgenesis CEO Vered Caplan featured in keynote series at INTERPHEX conference to discuss innovations in cell & gene therapy manufacturing
Germantown, MD, US, April 25, 2023 – Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene therapies (CGT) at the point of care, today announces Vered Caplan, CEO of Orgenesis, has been invited to participate in a keynote series, ‘applied continuous and modular manufacturing innovations,’ where she plans to discuss the latest innovations at the Company’s POCare Services subsidiary
25/04/2023
Minoryx presents positive interim results from NEXUS registration study for leriglitazone targeting pediatric ALD patients with cerebral adrenoleukodystrophy (cALD)
Mataró, Barcelona, Spain, April 25, 2023 - Minoryx Therapeutics, a registration-stage biotech company focused on the development of therapies for orphan central nervous system (CNS) disorders, today announces 24-week interim results from NEXUS.
25/04/2023
TrakCel extends ecosystem to integrate lead product OCELLOS with additional cell and gene therapy platforms and systems
Cardiff, UK, April 18, 2023 - TrakCel, the leading supplier of cellular orchestration solutions for clinical trials and commercial therapies to the cell and gene therapy (CGT) industry, today announces its latest update to OCELLOS, its lead advanced therapy orchestration product, via additions to the TrakCel partner ecosystem.
18/04/2023
BioSenic receives key European patent from EPO, for further therapeutic development in cancer, infectious and immune diseases
Mont-Saint-Guibert, Belgium, April 18, 2023 – BioSenic (Euronext Brussels and Paris: BIOS), the clinical stage company specializing in serious autoimmune and inflammatory diseases and cell repair, today announces the issuance of a key new patent entitled ‘Use of metal ions to potentiate the therapeutic effects of arsenic’ (EP3972613) by the European Patent Office (EPO).
18/04/2023
Immutep announces initiation of investigator-initiated Phase II trial in soft tissue sarcoma in neoadjuvant setting
Sydney, Australia, April 17, 2023 - Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces the initiation of an open-label Phase II trial evaluating eftilagimod alpha (efti), a soluble LAG-3 protein and MHC Class II agonist, in combination with pembrolizumab and radiotherapy in up to 40 soft tissue sarcoma (STS) patients in the neoadjuvant (prior to surgery) setting.
17/04/2023
Immutep announces changes to the board
Sydney, Australia, April 11, 2023 – Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune diseases, today announces that Lis Boyce has been appointed as Non-Executive Director. She replaces Lucy Turnbull who re-joined the board after the sudden and untimely death of Grant Chamberlain in January 2022.
11/04/2023
BioSenic appoints Lieven Huysse, MD, as Chief Medical Officer
Appointment to drive late-stage clinical development of BioSenic’s cell therapy and autoimmune disease platforms
03/04/2023
ISCT 2023 Paris harnessing global expertise and enabling collaboration to drive advanced therapies to patients
Vancouver, Canada, April 3, 2023 - The International Society for Cell & Gene Therapy (ISCT), the global society of over 3000 members dedicated to the translation of cell and gene therapies (CGT) into safe and effective treatments to improve patient lives, today announces it will host the largest translation-focused event connecting academic, regulatory and industry experts from around the world to collaborate and find tangible solutions to the most critical issues affecting the development of advanced therapies.
03/04/2023
Immutep announces positive final data in second-line metastatic NSCLC patients refractory to anti-PD-(L)1 therapy at European Lung Cancer Congress 2023
Sydney, Australia, March 31, 2023 – Immutep Limited (ASX: IMM; NASDAQ: IMMP), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces positive final data from Part B of the TACTI-002 Phase II trial in 2nd line metastatic non-small cell lung cancer (NSCLC) patients refractory to anti-PD-(L)1 therapy via a Mini Oral presentation at ESMO’s European Lung Cancer Congress (ELCC) 2023.
31/03/2023
BioSenic provides financial update and financial calendar 2023
Mont-Saint-Guibert, Belgium, March 31, 2023 - BIOSENIC (Euronext Brussels and Paris: BIOS), the clinical stage company specializing in severe autoimmune/inflammatory diseases and cellular repair, provides today a financial update and publishes its financial calendar for the year 2023.
31/03/2023
Immutep announces expansion of triple combination therapy in first-line non-small cell lung cancer
Expanding INSIGHT-003 trial evaluating efti with standard-of-care combination of anti-PD-1 therapy and chemotherapy to 50 patients
Expansion based on safety and strong initial efficacy results
Data updates expected throughout CY2023 and a cost-efficient approach through investigator-initiated trial will further inform options related to 1L NSCLC development
Clinical data to date shows efti uniquely positioned to address entire NSCLC patient population through both chemo-free IO-IO and IO-IO-chemo triple combinations
30/03/2023
BioSenic publishes new data on the mechanism of action of arsenic trioxide (ATO)
Combination of ATO with copper salts will allow BioSenic to work towards reducing the dosage of ATO in future trials overall and maintain efficacy
30/03/2023
TrakCel and Lonza complete integration milestone to combine cell and gene therapy manufacturing and orchestration solutions
Cardiff, UK, March 17, 2023 - TrakCel, the leading supplier of cellular orchestration solutions for clinical trials and commercial therapies to the cell and gene therapy (CGT) industry, today announces the latest milestone in the collaboration between TrakCel and Lonza, a global development and manufacturing partner to the pharma, biotech and nutrition industries.
17/03/2023
BioSenic delivers a new post-hoc analysis of its Phase III JTA-004 trial on knee osteo-arthritis with positive action on the most severely affected patient population
New analysis and formal identification of patient subsets open up further potential clinical development options for JTA-004
Mont-Saint-Guibert, Belgium, March 16, 2023 - BIOSENIC (Euronext Brussels and Paris: BIOS), the clinical stage company specializing in severe autoimmune/inflammatory diseases and cellular repair, announces today it has re-evaluated the results of its Phase III trial of its enhanced viscosupplement JTA-004 targeting knee osteoarthritis (OA).
16/03/2023
Orgenesis signs MOU with University of California, Davis to develop a collaboration agreement to deploy cell and gene therapy Mobile Processing Units and Labs across California
Germantown, Maryland, US, March 15, 2023 – Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene therapies (CGT) at the point of care, today announces the signing of a non-binding memorandum of understanding (MOU) with University of California, Davis (UC Davis).
15/03/2023
Immutep announces initiation of phase II/III trial for eftilagimod alpha plus paclitaxel in metastatic breast cancer
Sydney, Australia, March 14, 2023 – Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announced the initiation of AIPAC-003 (Active Immunotherapy, Eftilagimod Alpha, and Paclitaxel), an integrated Phase II/III trial to evaluate eftilagimod alpha (“efti”) in combination with paclitaxel for the treatment of metastatic HER2-neg/low breast cancer (MBC).
14/03/2023
Terumo Blood and Cell Technologies presents first Quantum Flex data for multiple size bioreactors showing rapid T-Cell expansion to numbers equivalent to a therapeutic dose
Lakewood, Colorado, February 23, 2023 – Terumo Blood and Cell Technologies (Terumo BCT), a medical technology company, for the first time today shared data generated from its Quantum Flex Cell Expansion System at a major conference, demonstrating how its hollow-fiber perfusion technology accelerates T-cell therapy development in a variety of bioreactors. In today’s presentation at CAR-TCR Summit Europe in London, Terumo BCT scientists detailed the outcome of multiple T-cell expansion runs, with a 60 percent to 70 percent reduction in media usage and 8.7 to 9.6 population doublings over the course of 8 days.
23/02/2023
BioSenic optimizes statistical analysis for its ongoing ALLOB Phase IIb study for high-risk tibial fractures, requiring fewer patients and completes patient recruitment
Mont-Saint-Guibert, Belgium, February 23, 2023 – BioSenic (Euronext Brussels and Paris: BIOS), the clinical stage company specializing in serious autoimmune / inflammatory diseases and cell repair, today announces a positive update to its ongoing Phase IIb clinical trial with its allogeneic bone cell therapy product, ALLOB.
23/02/2023
eXmoor pharma and vaccine developer Imophoron sign process development partnership
Multi-phase partnership will aim to manufacture vaccines for clinical use in eXmoor’s new facility to be launched in Q3, 2023
Bristol, UK, February 22, 2023 – eXmoor pharma, the cell and gene therapy partner specializing in accelerating the manufacturing journey from research to patients and Imophoron, the developer of a novel, next generation thermostable vaccine platform, ADDomer(TM), to combat present and future infectious diseases, today announce the signature of a strategic process development partnership that includes a future GMP manufacturing route.
22/02/2023
BioSenic receives EUR 1 million from Pregene in accordance with terminated license agreement and expect new negotiations on common revisited grounds
Mont-Saint-Guibert, Belgium, February 21, 2023 – BioSenic (Euronext Brussels and Paris: BIOS), the clinical stage company specializing in serious autoimmune / inflammatory diseases and cell repair, today announces it has received EUR 1 million (minus 6 percent taxes) from Pregene.
21/02/2023
Terumo Blood and Cell Technologies’ IMUGARD Platelet Pooling Set cleared by FDA
IMUGARD to help strained US platelet supply meet growing need
Lakewood, Colorado, US, February 14, 2023 – Terumo Blood and Cell Technologies announces US Food and Drug Administration (FDA) clearance and official launch of its IMUGARD(R)WB Platelet Pooling Set.......
14/02/2023
BioSenic announces the approval and publication of the Prospectus for listing and admission to trading of the shares and subscription rights issued in the context of the capital increase by way of in kind contributions of Medsenic 51 percent participation
Mont-Saint-Guibert, Belgium, February 8, 2023 – BioSenic (Euronext Brussels and Paris: BIOS), the clinical stage company specializing in serious autoimmune / inflammatory diseases and cell repair, today announces the publication of the Prospectus for listing and admission to trading on Euronext Brussels and Euronext Paris of 90,668,594 new shares and 24,463,421 new subscription rights that were issued in the context of the capital increase by way of in kind contributions of the Medsenic majority participation which was approved on 24 October 2022.
08/02/2023
Immutep reaches enrolment target for INSIGHT-003 trial in first-line NSCLC
20 patients with first-line non-small cell lung cancer (1L NSCLC) now enrolled in the first triple combination therapy study of efti with standard-of-care combination of anti-PD-1 therapy and chemotherapy
Promising initial efficacy results showing a 72.7 percent response rate and 90.9 percent disease control rate reported at SITC 2022
Additional data is expected throughout calendar year 2023 and will further inform our next steps in 1L NSCLC
06/02/2023
BioCardia and CellProthera Enhance Collaboration for Development of ProtheraCytes(TM) for the Treatment of Acute Myocardial Infarction in Europe and Potential Early Access for Patients
Sunnyvale, California, US and Mulhouse, France, February 1, 2023 - BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, and CellProthera, a private developer of cell-based therapies to repair ischemic tissues, today announce an amendment to their Clinical Research Supply and Support Agreement.
01/02/2023
BioSenic appoints Yves Sagot as Independent Director
Mont-Saint-Guibert, Belgium, January 27, 2023 – BioSenic (Euronext Brussels and Paris: BIOS), the clinical stage company specializing in serious autoimmune / inflammatory diseases and cell repair, today announces the appointment of Yves Sagot as a Member of the Board and Independent Director.
27/01/2023
The Lancet Neurology publishes results from Minoryx Therapeutics Phase 2/3 ADVANCE clinical trial of leriglitazone in X-linked Adrenoleukodystrophy
Leriglitazone was well tolerated, and significant benefit was shown through clinically meaningful myelopathy endpoints and reduced progression of cerebral lesions
19/01/2023
BioSenic appoints Dr Carole Nicco as Chief Scientific Officer
Dr Nicco will oversee the development of pipeline across BioSenic’s cell therapy and autoimmune disease platform and will be responsible for R&D programs
18/01/23
Immutep achieves 50 percent enrollment milestone in randomised Phase IIb TACTI-003 trial for first-line head and neck cancer
Sydney, Australia, January 4th 2023 – Immutep Limited (ASX: IMM; NASDAQ: IMMP)("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces that it has enrolled and randomised over 50 percent of the planned 154 patients in the TACTI-003 Phase IIb trial.
04/01/2023